Canada markets close in 5 hours 59 minutes

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.6800+0.0050 (+0.74%)
As of 8:00AM CEST. Market open.
Full screen
Previous Close0.6750
Open0.6750
Bid0.6700 x 0
Ask0.6900 x 0
Day's Range0.6800 - 0.6800
52 Week Range0.3280 - 0.7250
Volume500
Avg. Volume119
Market Cap24.818M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.0650
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Canntab Receives Export License Approval from Health Canada
    CNW Group

    Canntab Receives Export License Approval from Health Canada

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.

  • Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
    CNW Group

    Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia

    * 3rd Patent Grant with Australia following the United States and Canada * Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited * Participation in Australia's Largest Cannabis Research StudyTORONTO, March 9, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No.

  • Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
    Newsfile

    Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.

    Toronto, Ontario--(Newsfile Corp. - March 3, 2021) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE:TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape ...